Founded with the mission to revolutionize cystic fibrosis (CF) treatment, Sionna Therapeutics focuses on developing novel small molecule therapies. The company aims to fully normalize CFTR function, specifically targeting the most common genetic mutation affecting CF patients, ΔF508. As a clinical-stage company, Sionna Therapeutics is dedicated to advancing its pipeline through various stages of drug development, from discovery and lead optimization to DC/IND-enabling and clinical phases.
Sionna Therapeutics has garnered attention for its innovative approach and commitment to excellence in patient care. The company is supported by a team of experts in the field of cystic fibrosis and has attracted significant investment from leading healthcare investors. Its groundbreaking work has the potential to significantly impact the lives of CF patients by addressing the underlying genetic causes of the disease, aiming for a future where CFTR function is fully normalized.
